Multicompartimental nanoparticles for co-encapsulation and multimodal drug delivery to tumor cells and neovasculature.

about

Multicompartimental nanoparticles for co-encapsulation and multimodal drug delivery to tumor cells and neovasculature.

Item

http://www.wikidata.org/entity/Q45374613

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Multicompartimental nanopartic ...... umor cells and neovasculature.

@en

Multicompartimental nanopartic ...... umor cells and neovasculature.

@nl

type

Item

label

Multicompartimental nanopartic ...... umor cells and neovasculature.

@en

Multicompartimental nanopartic ...... umor cells and neovasculature.

@nl

prefLabel

Multicompartimental nanopartic ...... umor cells and neovasculature.

@en

Multicompartimental nanopartic ...... umor cells and neovasculature.

@nl

P1476

Multicompartimental nanopartic ...... umor cells and neovasculature.

@en

P2093

Bruna Dos Santos Rodrigues

http://www.w3.org/2001/XMLSchema#string

Lílian Cristina Rosa Dos Santos

http://www.w3.org/2001/XMLSchema#string

Lívia Palmerston Mendes

http://www.w3.org/2001/XMLSchema#string

Marcelo de Sousa Vieira

http://www.w3.org/2001/XMLSchema#string

Marilisa Pedroso Nogueira Gaeti

http://www.w3.org/2001/XMLSchema#string

Paulo Henrique Marcelino de Ávila

http://www.w3.org/2001/XMLSchema#string

Renato Ivan de Ávila Marcelino

http://www.w3.org/2001/XMLSchema#string

P2860

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Tumor angiogenesis: therapeutic implications

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems--a review.

Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.

Lipid bilayer thickness varies linearly with acyl chain length in fluid phosphatidylcholine vesicles.

Inhibition of cancer cell invasion and metastasis by genistein

Antiangiogenic therapy and tumor progression.

Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study

P304

1106-1119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-013-1234-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eliana Martins Lima

M C Valadares

P577

2013-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258147938

http://www.w3.org/2001/XMLSchema#string

P698

24170281

http://www.w3.org/2001/XMLSchema#string

P921

drug delivery